One dose of HPV vaccine may be enough, Australian research finds

July 24, 2019

One dose of human papillomavirus (HPV) vaccine has comparable effectiveness to two or three doses for preventing cervical pre-cancer, according to a new study.

In a large national data linkage study published in Papillomavirus Research, researchers compared cervical screening outcomes for a quarter of a million Australian women who were eligible for vaccination under the national program.

Researchers found that in women who were vaccinated at a young age, when most had not yet been exposed to HPV, that receipt of even one dose of HPV vaccine lowered the chance of having a pre-cancerous lesion detected at cervical screening.

Lead author Julia Brotherton from the VCS Foundation and the University of Melbourne said this data adds to other evidence starting to emerge that one dose of HPV vaccine may eventually prove to be sufficient for protection.

"If one dose vaccination proves to be enough, it will really simplify our ability to protect more people against these cancer-causing viruses," Associate Professor Brotherton said.

"That could make a huge difference, especially in less well-resourced countries that currently have high rates of cervical cancer but can't currently afford vaccination or screening."

However, Associate Professor Brotherton emphasised that until the results of formal trials were in and recommendations changed, that young people should make sure that they complete the two-dose vaccination course currently in place for best protection.

"The HPV vaccine has proven itself to be both very safe and remarkably effective," Associate Professor Brotherton said.

"We are proud that Australia is contributing data from our world leading program to add to the evidence on this issue."

Vaccination is a key part of the World Health Organisation's recent call to work towards the elimination of cervical cancer as a public health problem, together with HPV based screening, facilities for early diagnosis and treatment, and palliative care.

In Australia, HPV vaccination is routinely offered free of charge under the National Immunisation Program to both girls and boys in early high school at age 12-13 years, with free catch up available up to the age of 19 through local doctors and clinics.

As in Australia, most countries are only now beginning to be able to assess the vaccine's impact on screening outcomes from the vaccination of girls at the routine target age rather than in young women who were already sexually active prior to vaccination.

Recent data from Denmark and the US also support the possibility that one dose may be sufficient, but results of randomised trials are awaited before official recommendations are changed.

The data was analysed by a team of researchers from the VCS Foundation, the Australian Institute of Health and Welfare and cervical screening program managers from the ACT, NT, Tasmania, Victoria and Western Australia.

Background notes:
-end-


University of Melbourne

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.